摘要
目的:研究溴隐亭不同给药方案在治疗高泌乳素血症(HPRL)女性不育症中的临床疗效,关注其对女性促性腺激素诱导排卵的影响。方法:本研究共纳入60例就诊于我院的确诊为高泌乳素血症不孕不育患者,随机分为两组。分为研究组与对照组:研究组采取先口服溴隐亭调整血清泌乳素水平至正常后予以促性腺激素诱导排卵;对照组采取促性腺激素与溴隐亭同步治疗方案。结果:观察两组患者的促排卵周期数、平均用药天数、雌二醇水平及妊娠率,两组治疗前后的血清泌乳素都显著改善(P<0.05);但是两组之间相比,采取溴隐亭药物治疗后诱导排卵的研究组在促排卵、雌二醇水平和妊娠率方面具有显著优势(P<0.05)。结论:采用溴隐亭治疗高泌乳素血症患者,调整至正常后再使用促卵泡激素药物促排卵治疗不孕不育具为较优的治疗方案。
Objective： The purpose of the experiment is to study the clinical efficacy of bromocriptine different dosing regimens in the treatment of hyperprolactinemia（HPRL） female infertility, and focus on its impact on women gonadotropin ovulation induction.Methods： The study included patients in our hospital diagnosed 60 cases of hyperprolactinemia infertility patients were randomly divided into two groups. Study Group to take the first oral bromocriptine adjusted serum prolactin levels to be normal after ovulation induction gonadotropin; gonadotropin take control and synchronization bromocriptine treatment. Results： The number of ovulation cycles were observed, and the average number of days of medication, estradiol levels and pregnancy, serum prolactin before and after treatment were significantly improved（P〈0.05）; but compared between the two groups, take bromocriptine Pavilion after drug treatment to induce ovulation research group has significant advantages（P〈0.05） in ovulation, estradiol levels and pregnancy terms. Conclusions： Using bromocriptine treatment of hyperprolactinemia patients adjust to normal before using follicle stimulating hormone drugs ovulation infertility treatment with the optimum treatment.
出处
《现代生物医学进展》
CAS
2017年第1期130-132,144,共4页
Progress in Modern Biomedicine
基金
首都卫生发展科研专项基金项目(2016-2-2113)
作者简介
王娟（1974-），女，医学学士，主要研究方向：妇科内分泌，E·mail：dIjuanwang@163．com
通讯作者：李金梁（1978-），男，硕士生导师，副教授，主要研究方向：心血管内科，E—mail：18545584169@163．com，电话：18545584169
